vida: extract claims from 2026-04-28-glp1-managed-access-operating-systems-payer-infrastructure

- Source: inbox/queue/2026-04-28-glp1-managed-access-operating-systems-payer-infrastructure.md
- Domain: health
- Claims: 2, Entities: 2
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md

@@ -12,9 +12,16 @@ scope: causal
 sourcer: JMIR / Omada Health
 supports: ["healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create"]
 challenges: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics"]
-related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-long-term-persistence-ceiling-14-percent-year-two"]
+related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-long-term-persistence-ceiling-14-percent-year-two", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring"]
 ---
 
 # Digital behavioral support improves GLP-1 persistence by 20 percentage points (67% vs 47% at 12 months) through integrated coaching and monitoring
 
 Two converging data sources demonstrate that digital behavioral support substantially improves GLP-1 medication persistence. Omada Health's Enhanced GLP-1 Care Track showed 67% of members persistent on medication at 12 months, compared to baseline real-world evidence of 47-49% persistence without digital support—a 20 percentage point improvement. The JMIR 2025 peer-reviewed study (e69466) independently confirmed that engagement with digital weight management platforms significantly enhances weight loss outcomes among GLP-1 users. Weight loss outcomes also improved: 18.4% average weight loss with digital support versus 11.9% in standard real-world evidence, matching clinical trial results. A ~65,000-user dataset showed hybrid human-AI coaching produced 74% more weight loss than AI-only coaching over 3 months, suggesting the human coaching layer drives marginal adherence improvement. The mechanism appears to be behavioral support addressing the non-pharmacological barriers to persistence: side effect management, lifestyle integration, and accountability. This is distinct from the drug's pharmacological effect and represents a separable value layer. Important caveat: The 67% figure comes from Omada's proprietary platform data, not independent verification, though the JMIR peer-reviewed paper provides directional corroboration.
+
+
+## Extending Evidence
+
+**Source:** on/healthcare.tech, UHC Total Weight Support program structure
+
+UHC Total Weight Support now requires coaching engagement (Real Appeal Rx or WeightWatchers) as a COVERAGE PREREQUISITE, not optional support. This represents evolution from behavioral support improving persistence to behavioral participation as a structural access gate. 34% of 5,000+ employee firms now require behavioral participation as coverage condition, up from 10% in 2024.

domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -74,3 +74,10 @@ WHO explicitly states that current global access and affordability for GLP-1s ar
 **Source:** ICER Final Evidence Report, December 2025
 
 ICER report documents the access inversion at policy level: California Medi-Cal (serving lowest-income population) eliminated coverage January 2026 despite 14-0 clinical evidence. Medicare coverage restricted to cardiovascular risk indication, excluding pure obesity. National Pharmaceutical Council criticized ICER for 'prioritizing payers over patients,' highlighting the structural tension between budget sustainability and individual access. The 14-0 clinical verdict combined with simultaneous coverage elimination is the clearest expression of structural misalignment.
+
+
+## Supporting Evidence
+
+**Source:** on/healthcare.tech coverage expansion analysis
+
+Coverage expansion data shows 43% of 5,000+ employee firms now cover GLP-1s for weight loss (up from 28% in 2024), while state mandates are emerging (North Dakota January 2025, California/Connecticut/West Virginia introducing legislation). However, Medicare Part D coverage doesn't begin until January 2027, and Medicaid coverage is reversing through state budget pressure. This confirms the access inversion where higher-income commercially insured populations gain access while lower-income populations face coverage contraction.

domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md

@@ -51,3 +51,10 @@ The biological mechanism underlying low persistence creates a clinical revolving
 **Source:** Truveta Research ISPOR 2025
 
 Truveta data shows the first 4 weeks (titration phase) are the highest-risk period for dropout, with persistence improving after initial titration but remaining below 50% for non-T2D patients. This temporal pattern suggests that interventions targeting the titration phase could disproportionately improve long-term persistence.
+
+
+## Supporting Evidence
+
+**Source:** on/healthcare.tech analysis, Prime Therapeutics via Mercer
+
+Meta-regression data cited by on/healthcare.tech shows ~50% discontinuation within one year, ~60% weight regain within 12 months of cessation, and 1-in-12 patients (8.3%) remaining on therapy at three years according to Prime Therapeutics data cited by Mercer. This confirms the year-two persistence ceiling and extends the timeline to show continued attrition through year three.

domains/health/glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary.md

@@ -0,0 +1,33 @@
+---
+type: claim
+domain: health
+description: Payers are building multi-layer infrastructure (access, behavioral, contracting, manufacturer-direct) to manage GLP-1 as a system rather than a drug
+confidence: likely
+source: on/healthcare.tech analysis, Evernorth EncircleRx 9M lives, UHC Total Weight Support, Optum Rx Weight Engage operational data
+created: 2026-04-28
+title: GLP-1 economics require managed-access operating systems beyond standard formulary because eligible population scale, cost structure, and multi-indication complexity demand continuous operational management across eligibility, behavioral gates, and discontinuation protocols
+agent: vida
+sourced_from: health/2026-04-28-glp1-managed-access-operating-systems-payer-infrastructure.md
+scope: structural
+sourcer: on/healthcare.tech
+supports: ["glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring"]
+related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-long-term-persistence-ceiling-14-percent-year-two", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics"]
+---
+
+# GLP-1 economics require managed-access operating systems beyond standard formulary because eligible population scale, cost structure, and multi-indication complexity demand continuous operational management across eligibility, behavioral gates, and discontinuation protocols
+
+Traditional formulary yes/no structure cannot accommodate GLP-1 economics at scale. The eligible commercially insured population is 36.2 million adults, with recurring costs of $1,000-$1,200+/month and expanding indications (obesity, T2D, cardiovascular risk 2024, MASH F2-F3 fibrosis 2025, sleep apnea December 2024). This creates a decision tree requiring continuous management: which populations qualify, under what thresholds, through which channels, with what behavioral gates, at what subsidy levels, with what discontinuation rules.
+
+Payers are responding by building managed-access operating systems with distinct infrastructure layers:
+
+1. **Access layer**: Evernorth EncircleRx manages 9 million enrolled lives with 15% cost cap or 3:1 savings guarantee, saving ~$200 million since 2024. This is utilization management infrastructure, not formulary.
+
+2. **Behavioral coaching layer**: Optum Rx Weight Engage pairs GLP-1 access with obesity specialist navigation and coaching. UHC Total Weight Support requires coaching engagement (Real Appeal Rx or WeightWatchers) as a COVERAGE PREREQUISITE — behavioral participation is now a structural access gate, not an optional support.
+
+3. **Contracting layer**: Evernorth's cost cap and savings guarantee represent outcomes-based contracting frameworks that shift risk.
+
+4. **Manufacturer direct layer**: Eli Lilly Employer Connect (March 5, 2026) offers $449/dose Zepbound direct to employers through 15+ program administrator partnerships (GoodRx, Teladoc, Calibrate, Form Health, Waltz), bypassing PBMs entirely. Novo Nordisk launched parallel DTE channels January 1, 2026 via Waltz Health and 9amHealth.
+
+The persistence problem justifies this infrastructure investment: meta-regression data shows ~50% discontinuation within one year, ~60% weight regain within 12 months of cessation, and only 1-in-12 patients remaining on therapy at three years (Prime Therapeutics, cited by Mercer). Without behavioral gates, drug-only GLP-1 coverage is cost without durable benefit.
+
+Indication expansion creates additional complexity requiring distinct medical-necessity criteria and cost-offset narratives for each pathway. This is not a formulary problem — it's an operating system problem requiring continuous operational management.

domains/health/glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024.md

@@ -24,3 +24,10 @@ ICER's April 2025 white paper documents that self-insured employers offering GLP
 **Source:** PHTI Employer GLP-1 Coverage Market Trend Report, December 2025
 
 Employer response to GLP-1 cost pressure includes cost management strategies: step therapy, prior authorization, and lifestyle program requirements as coverage conditions. PHTI documents employers adopting 'scalable tech-enabled care with measurable outcomes' as the winning strategy in a 'high-pressure environment.' This shows payers are not simply cutting coverage but restructuring it around adherence and outcomes infrastructure to manage the fiscal burden.
+
+
+## Extending Evidence
+
+**Source:** on/healthcare.tech, Evernorth EncircleRx operational data
+
+Evernorth EncircleRx reports ~$200 million saved since 2024 across 9 million enrolled lives through 15% cost cap or 3:1 savings guarantee structure. This represents early evidence that managed-access infrastructure can contain costs, though the $200M savings across 9M lives (~$22/member) is modest relative to the 10x PMPM increase that created the fiscal pressure.

domains/health/manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression.md

@@ -0,0 +1,34 @@
+---
+type: claim
+domain: health
+description: Lilly Employer Connect and Novo Nordisk DTE channels at $449/dose vs $1,000+ retail create new distribution pathway outside PBM control
+confidence: experimental
+source: Eli Lilly Employer Connect March 5 2026, Novo Nordisk Waltz/9amHealth January 1 2026, on/healthcare.tech analysis
+created: 2026-04-28
+title: Manufacturer direct-to-employer GLP-1 channels launched 2026 represent structural challenge to PBM intermediation by offering 55-60 percent price compression while bypassing traditional pharmacy benefit architecture
+agent: vida
+sourced_from: health/2026-04-28-glp1-managed-access-operating-systems-payer-infrastructure.md
+scope: structural
+sourcer: on/healthcare.tech
+challenges: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
+related: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
+---
+
+# Manufacturer direct-to-employer GLP-1 channels launched 2026 represent structural challenge to PBM intermediation by offering 55-60 percent price compression while bypassing traditional pharmacy benefit architecture
+
+Eli Lilly launched Employer Connect on March 5, 2026, offering Zepbound at $449/dose directly to employers — a 55-60% discount versus $1,000+ retail pricing. The program operates through 15+ program administrator partnerships including GoodRx, Teladoc, Calibrate, Form Health, and Waltz, completely bypassing PBM intermediation. Novo Nordisk launched parallel direct-to-employer channels on January 1, 2026, via Waltz Health and 9amHealth partnerships.
+
+This represents a structural challenge to the traditional pharmacy benefit architecture where PBMs control formulary access, negotiate rebates, and manage utilization. By going direct to employers, manufacturers:
+
+1. **Eliminate PBM margin**: The $449 price point suggests manufacturers are willing to sacrifice margin to establish direct relationships
+2. **Control the access infrastructure**: Program administrators (Calibrate, Form Health, Waltz) provide the behavioral support and utilization management that PBMs were building
+3. **Capture the employer relationship**: Direct contracting positions manufacturers as benefit design partners, not just drug suppliers
+
+The timing is significant: these channels launched in Q1 2026, exactly when PBMs (Evernorth, Optum Rx) were building their own managed-access infrastructure. This suggests manufacturers recognized the strategic risk of PBMs controlling the access layer and moved to disintermediate.
+
+The durability of this model is uncertain (hence experimental confidence). Questions remain:
+- Can manufacturers sustain $449 pricing at scale?
+- Will employers accept the administrative complexity of direct contracting?
+- How will PBMs respond — price matching, exclusion, or regulatory challenge?
+
+But the structural challenge is real: if manufacturers can profitably deliver GLP-1s at 55-60% below retail while providing behavioral support infrastructure, the PBM value proposition in this category is threatened.

entities/health/evernorth-encirclerx.md

@@ -0,0 +1,33 @@
+# Evernorth EncircleRx
+
+**Type:** Managed-access program (PBM infrastructure)
+**Parent:** Evernorth (Cigna)
+**Domain:** GLP-1 utilization management
+**Status:** Active
+
+## Overview
+
+Evernorth EncircleRx is a managed-access operating system for GLP-1 receptor agonists, managing utilization and cost across 9 million enrolled lives as of 2026.
+
+## Program Structure
+
+**Cost containment mechanisms:**
+- 15% cost cap guarantee
+- 3:1 savings guarantee (alternative structure)
+- $200 copay cap on Wegovy and Zepbound (added 2025)
+
+**Operational scale:**
+- 9 million enrolled lives
+- ~$200 million saved since 2024
+
+## Strategic Context
+
+EncircleRx represents Evernorth's response to GLP-1 fiscal pressure (10x PMPM increase 2023-2024) by building multi-layer infrastructure beyond traditional formulary management. The program competes with:
+- Optum Rx Weight Engage (UHC)
+- Manufacturer direct-to-employer channels (Lilly Employer Connect, Novo Nordisk DTE)
+
+## Timeline
+
+- **2024** — EncircleRx launched
+- **2025** — Added $200 copay cap on Wegovy and Zepbound
+- **2026** — Managing 9M lives, ~$200M cumulative savings reported

entities/health/lilly-employer-connect.md

@@ -0,0 +1,43 @@
+# Eli Lilly Employer Connect
+
+**Type:** Direct-to-employer distribution channel
+**Parent:** Eli Lilly
+**Domain:** GLP-1 access infrastructure
+**Status:** Active
+**Launch:** March 5, 2026
+
+## Overview
+
+Eli Lilly Employer Connect is a direct-to-employer channel offering Zepbound at $449/dose (55-60% below retail pricing of $1,000+), bypassing traditional PBM intermediation.
+
+## Program Structure
+
+**Pricing:**
+- $449/dose Zepbound
+- 55-60% discount versus retail ($1,000+)
+
+**Distribution partners (15+):**
+- GoodRx
+- Teladoc
+- Calibrate
+- Form Health
+- Waltz
+- [Additional partners not specified in source]
+
+**Strategic positioning:**
+- Bypasses PBM formulary control
+- Provides behavioral support infrastructure through program administrator partnerships
+- Establishes direct manufacturer-employer relationship
+
+## Market Context
+
+Launched in parallel with Novo Nordisk direct-to-employer channels (January 1, 2026 via Waltz Health and 9amHealth), representing manufacturer response to PBM-controlled managed-access infrastructure.
+
+Competes with:
+- Evernorth EncircleRx
+- Optum Rx Weight Engage
+- UHC Total Weight Support
+
+## Timeline
+
+- **March 5, 2026** — Employer Connect launched with $449/dose pricing and 15+ program administrator partnerships

inbox/archive/health/2026-04-28-glp1-managed-access-operating-systems-payer-infrastructure.md

@@ -7,10 +7,13 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: analysis
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-28
 priority: high
 tags: [GLP-1, payer, infrastructure, managed-access, value-based-care, employer-benefits, utilization-management]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content